Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6388516rdf:typepubmed:Citationlld:pubmed
pubmed-article:6388516lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6388516lifeskim:mentionsumls-concept:C0013072lld:lifeskim
pubmed-article:6388516lifeskim:mentionsumls-concept:C0007202lld:lifeskim
pubmed-article:6388516lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:6388516lifeskim:mentionsumls-concept:C0033567lld:lifeskim
pubmed-article:6388516lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:6388516lifeskim:mentionsumls-concept:C0581603lld:lifeskim
pubmed-article:6388516pubmed:issue5lld:pubmed
pubmed-article:6388516pubmed:dateCreated1984-12-18lld:pubmed
pubmed-article:6388516pubmed:abstractTextProstacyclin (PGI2) has been suggested for use in cardiopulmonary bypass (CPB) because of its positive effects on platelet number and function. Fifty patients who underwent coronary artery bypass grafting using a bubble oxygenator received heparin, 3 mg per kilogram of body weight, and then were randomly assigned to receive PGI2, 25 ng/kg/min, beginning 5 minutes before and until the end of CPB (26 patients) or a placebo (24 patients). Both groups were similar in sex, age, heparin dose, protamine dose, and CPB time. During CPB, mean arterial pressure fell significantly with PGI2 (76 +/- 2 mm Hg to 53 +/- 2 mm Hg; p less than 0.05) and necessitated pressor substances. Platelet counts fell significantly in both groups with the start of CPB, but after 60 minutes were similar in both groups (118 +/- 9 X 10(3) versus 130 +/- 8 X 10(3); not significant [NS]) and were unchanged 3 hours after CPB. Total chest tube output was 647 +/- 51 ml (placebo group) versus 576 +/- 34 ml (PGI2 group) (NS); 18 of the patients given PGI2 required 26 transfusions compared with 16 transfusions in 8 of the patients given a placebo (p less than 0.05). In PGI2 patients, arterial oxygen tension on 100% oxygen fell from 281 +/- 18 mm Hg before CPB to 223 +/- 17 mm Hg immediately after CPB (p less than 0.05). The placebo patients did not show a change in this variable.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:6388516pubmed:languageenglld:pubmed
pubmed-article:6388516pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6388516pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6388516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6388516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6388516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6388516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6388516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6388516pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6388516pubmed:statusMEDLINElld:pubmed
pubmed-article:6388516pubmed:monthNovlld:pubmed
pubmed-article:6388516pubmed:issn0003-4975lld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:JonasRRlld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:HechtmanH BHBlld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:CollinsJ...lld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:FOITRRlld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:SheminR JRJlld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:Lee-SonSSlld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:MaddiRRlld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:LelcukSSlld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:DiSesaV JVJlld:pubmed
pubmed-article:6388516pubmed:authorpubmed-author:HuvalWWlld:pubmed
pubmed-article:6388516pubmed:issnTypePrintlld:pubmed
pubmed-article:6388516pubmed:volume38lld:pubmed
pubmed-article:6388516pubmed:ownerNLMlld:pubmed
pubmed-article:6388516pubmed:authorsCompleteYlld:pubmed
pubmed-article:6388516pubmed:pagination514-9lld:pubmed
pubmed-article:6388516pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:meshHeadingpubmed-meshheading:6388516-...lld:pubmed
pubmed-article:6388516pubmed:year1984lld:pubmed
pubmed-article:6388516pubmed:articleTitleDisadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization.lld:pubmed
pubmed-article:6388516pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6388516pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:6388516pubmed:publicationTypeRandomized Controlled Triallld:pubmed